PPT-Prasugrel vs ticagrelor in acute coronary syndromes

Giuseppe BiondiZoccai MD Sapienza University of Rome Italy giuseppebiondizoccaiuniroma1it Learning goals Scope of the problem Prasugrel Ticagrelor Reconciling the . safety study . of . ticagrelor's. degradation combining . LC-MS and . in . silico. approach. H. SADOU YAYE*, B. DO, N. YAGOUBI. * . Pharmacist at . Pitié-Salpêtrière. Hospital (Paris) . P. hD student – University Paris . Objectifs pédagogiques. Quelle est l’anatomo-physiologie de la moelle épinière?. Quelles sont les manifestations cliniques d’une atteinte médullaire?. Comment reconnaitre un syndrome médullaire?. Ticagrelor. for Secondary Prevention: . Insights from PEGASUS-TIMI 54 Trial . Marc P. . Bonaca. , MD, MPH. on behalf of the . PEGASUS-TIMI 54 . Executive & Steering Committees and Investigators. Ticagrelor. in Diabetic Patients from the PEGASUS-TIMI 54 Trial. Deepak L. Bhatt, MD, MPH, Marc P. Bonaca, MD, MPH, Sameer Bansilal, MD, . MS, . Dominick J. Angiolillo. , . MD, PhD, Marc Cohen, MD, Robert F. Storey, MD, Kyungah Im, PhD, Sabina A. Murphy, MPH, Peter Held, MD, PhD, Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH, Ph. Gabriel Steg . September 29. th. 2014. Goals and Objectives. Review the . etiologies . of Acute Coronary Syndrome (ACS). Gain understanding of how to diagnose ACS. Understand the different types of ACS. Review the treatment of ACS. Cedar Mountain post acute rehabilitation center provide a therapeutic environment for our residents Yucaipa. Individualized treatment programs are developed with the interdisciplinary team of nursing, social services, Healthcare and dietary in consultation with your physicians. ACCOAST: no difference in efficacy endpoint between pretreatment with prasugrel or no pretreatment Montalescot et al. NEJM 2013 ACCOAST: All TIMI major bleeding after pretreatment ACCP Cardiology PRN Journal Club 27 September 2019 Presenter Bio Dr. Maxwell Ditlevson is a PGY2 Cardiology Resident at the The Johns Hopkins Hospital. He completed his PGY1 Pharmacy Practice Residency at The Johns Hopkins Hospital too. Max received his Associate Professor of Clinical Pharmacy,. SBMU. CLASSIFICATION OF ANTIPLATELET AGENTS. Cyclooxygenase inhibitors. Aspirin. Platelet . P2Y12 receptor . blockers. clopidogrel, . ticlopidine. , . ticagrelor. Coronary Artery Disease. . Includes stable angina and acute coronary syndromes. Ischemia. —. insufficient oxygen supply to meet the requirements of the myocardium. Infarction. —. necrosis or cell death that occurs when severe ischemia is prolonged and decreased perfusion causes irreversible damage to tissue. Prof. Dr. . Kurt Huber. , MD. Sigmund Freud University, Medical Faculty, and Wilhelminenspital . Vienna, Austria. 2. Please note: . The views expressed within this presentation are the personal opinions of the authors. . Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. 1. ; Fabiana Rollini, MD1, Mattia Galli, MD. 1. ,. 2. Latonya Been, AAS. 1. , Ghussan Ghanem, MD. 1. , . Awss. . Shalhoub. , MD. 1. , Tiffany Ossi, MD. Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial. Gregg W Stone MD. Icahn School of Medicine at Mount Sinai. on behalf of Shao-Liang Chen and the ULTIMATE-DAPT Investigators. Assist.lec. . . Shaymaa. . Hasan. Abbas. Ischemic Heart Disease. The major goals for the treatment of IHD are to:. • Prevent acute coronary syndromes and death . • Alleviate acute symptoms of myocardial ischemia.